Cipla Undergoes USFDA Inspection at Goa Facility; Issues Two Observations
Cipla Ltd has reported that its manufacturing facility in Verna, Goa, India, underwent a USFDA inspection. The inspection took place over an eleven-day period, spanning from April 6 to April 17, 2026.The inspection covered both a routine Current Good Manufacturing Practices (cGMP) review and a Pre-Approval Inspection (PAI).
Following the completion of the audit, the company received two inspectional observations, detailed in Form 483. Cipla stated that it is committed to addressing these observations comprehensively and will work closely with the USFDA to resolve the matters within the stipulated time.
CIPLA Stock Price Movement
Today, Cipla Limited shares edged higher, settling at ₹1240.8 after gaining 1.14% on the day's trading. The stock recorded a volume of 2.29 million shares, indicating sustained interest in the pharmaceutical giant.Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.